Rare disease drug launches are more common than ever. Commercial teams will continue to need rare disease drug launch expertise, as over a third of industry R&D pipeline are orphan drugs. Preparing for a rare disease drug launch is more challenging than ever before with increased competition, price pressures, and customer expectations. Success in rare disease drug launch depends on early preparation, tailored strategy, and an exquisite understanding of and responsiveness to customer needs.
With a $131 billion market valuation and 11% growth rate, it’s clear why rare disease product launch has increased. Commercial attractiveness of rare disease drug launches stems from high price points, increased exclusivity and R&D tax and cost benefits. Orphan drug designation enables 7-10-year market exclusivity and an asset can hold orphan designations across several indications.
This webinar will focus on key challenge areas and critical success factors in rare disease launch readiness including accurate opportunity sizing, engaging advocates, managing accelerated review timelines and access challenges. Our industry and professional services speakers will share lessons learned from real examples of rare disease launch readiness efforts.
Beth Schurman, Partner, Herspiegel Consulting
Beth Schurman has helped to grow Herspiegel Consulting during the last 12 years into a world-class firm helping clients with commercial strategy, innovation, and execution. She has been involved in new product commercialization and brand optimization across oncology, CNS, metabolic disease, dermatology, women’s and men’s’ health from rare disease to blockbuster brands. Prior to Herspiegel Consulting, Schurman worked on the client side in marketing roles at Bristol-Myers Squibb and Novo Nordisk.Message Presenter
Jennifer Beachell, Vice President Commercial, Momenta Pharmaceuticals
Jen Beachell is the vice president of global commercial strategy at Momenta Pharmaceutical. Beachell has led commercial organizations and teams over a 20-year career in the biopharma industry. At Momenta, Beachell and the team are preparing to launch nipocalimab across three indications in different therapeutic areas, including hemolytic disease of the fetus and newborn, a rare disease that affects pregnant women and families. Beachell’s expertise spans the commercial disciplines of market access, pricing, positioning, sales, promotion, and patient services. Beachell is recognized as a commercialization expert with both early strategy and late stage experience, including launching Benysta, FluMist, OrthoVisc, and relaunching Juxtapid and Myalept. Beachell also has a background in digital health, direct-to-consumer marketing and healthcare policy.Message Presenter
Who Should Attend?
Director and Senior Level professionals from biopharmaceutical companies working within:
- Pharmaceutical and Biotech Commercial Leaders of Marketing
- Market Access
- Medical Affairs and Commercial Operations Teams
- Omnichannel, Brand, and Market-Shaping Leaders.
- Director, VP, and C-Suite Level Executives
What You Will Learn
- Critical areas of focus for successful rare disease product launch
- Building strong connections with HCPs, patients, and advocacy organizations
- The new approach for access strategy in rare disease
- Focused planning and execution with small teams
Herspiegel Consulting specializes in pharmaceutical and biotech commercialization helping clients in with strategy through execution in five core service areas of new product planning, marketing, launch readiness, medical affairs, and market access. Herspiegel Consulting offers integrative, tailored consulting services to meet your brand and business needs. Our diverse team brings experience from over 65 product launches strategy and innovation leadership, and executional support for start-up to large pharma clients. We have experience across a wide variety of therapeutic areas including oncology, rare disease, metabolic disease, CNS, women’s health, and others.